No potential conflicts of interest were disclosed. and have a mortality rate of 45%. We have previously shown that E2F7 may contribute to drug resistance in SCC cells. However, the mechanism and pathways involved remain unknown.
Introduction
Head and neck squamous cell carcinomas (HNSCC) arise from stratified squamous epithelia of the mucosae of the upper aerodigestive tract. At present the mainstay of treatment for advanced HNSCC is surgery and/or radiation plus adjuvant chemotherapy (1). The use of adjuvant chemotherapy provides modest improvements to overall survival but are not considered curative in their own right (1). Thus, if we are to improve outcomes in patients with advanced HNSCC we need to develop systemic therapies that target novel pathways activated in HNSCC cells.
HNSCC is a complex cancer associated with a large mutational burden (2, 3) and accompanied by dysregulation of proliferation, differentiation and apoptosis. HNSCC is also accompanied by dysregulation of the main functions of the E2F transcription factor family (4, 5) . E2F refers to a family of 10 gene products from 8 genes (E2Fs 1, 2, 3a, 3b, 4, 5, 6, 7a, 7b, 8) that have been broadly divided into activators (E2F1-E2F3a) and inhibitors (E2F3b and E2F4-E2F8) (6) . The E2F family regulates a diverse array of functions such as proliferation, differentiation, apoptosis and stress responses (7, 8) . The way in which the E2F family coordinate such diversity of action is through isoform specific functions of the individual E2Fs (e.g. activators vs inhibitors) coupled with context-specific interacting partner proteins such as pocket proteins and HDACs (7, 8) . In the context of keratinocytes (KCs), it has been shown that normal human and murine KCs express all members of the E2F family with the exception of E2F6 (9, 10) . It has been shown that proliferation and differentiation of KCs is regulated by the opposing actions of E2F1 and E2F7 (4, 9, 11, 12) . Significantly, E2F1 and E2F7 are overexpressed in patient SCCs (10) and contribute to the development of cutaneous SCC (13, 14) .
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Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 In addition, to the role of E2Fs in proliferation and differentiation, E2Fs are also key regulators of apoptosis and stress responses (7, 8) . For example, E2F1 has been shown to have potent pro-apoptotic actions that regulate the numbers of thymic lymphocytes (15) .
Intriguingly, E2F1 mediated-apoptosis has been reported to be via p53-dependent and p53-independent pathways (16) suggesting that cellular context may determine the mechanism by which E2F1 induces apoptosis. More recently, E2F7 was reported to antagonise the proapoptotic actions of E2F1 in the context of etoposide or doxorubicin induced DNA damage (10, 17) . Thus, the ratio of E2F1 to E2F7 determines apoptotic responses. However, the mechanism by which E2Fs control apoptotic responses remains unknown. In the present study, we examined downstream effectors of E2F7 that modulate resistance to chemotherapy.
We now identify a previously undescribed E2F7/Sphk1/S1P/AKT axis that contributes to anthracycline resistance in SCC. In addition, we identify a novel drug combination that could represent a potentially curative option for advanced SCC.
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Materials and Methods

Animal studies
All animal experiments were approved by the Institutional Animal Ethics Committee.
E2F7 Flox/Flox
, E2F8
Flox/Flox and E2f1 KO mice have been described (15, 18) . FVB X C57BL/6 crosses were generated in house. In vivo tumour studies used female nonobese diabetic/severe combined immunodeficient (NOD/SCID).
Reagents and viability assays
The following drugs were purchased; doxorubicin (Sigma Aldrich), SK1-I (BML-EI411) (Enzo Life Sciences), S1P (Cayman Chemicals). Stocks of BGT226 were prepared as described (19) . Viability was determined using trypan blue, Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega), or western blot for cleaved caspase 3 or PARP cleavage as described (20, 21) . Sphk1 activity and S1P levels were estimated using commercially available kits (Echelon Biosciences).
Tissue culture and adenovirus infection
Murine epidermal keratinocytes (MEKs) and human epidermal keratinocytes (HEKs) were isolated and cultured as described (22, 23) . SCC25 cells were obtained from the American Type Culture Collection. FaDu was a kind gift from Dr. Elizabeth Musgrove (Garvan Institute, New South Wales, Australia) and were verified by short tandem repeat genotyping (11) . KJDSV40 cells were maintained as described previously (11) . To generate E2F7 and E2F8 KO keratinocytes, we incubated MEKs with ready-to-use Ad-CMV-Cre as per manufacturer's recommendations (MOI of 50) (Vector Biolabs).
Gene expression studies
Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 Total RNA was isolated, cDNA prepared and quantitative reverse transcriptase PCR (qRT-PCR) performed as described (10, 24) . For microarray analysis, complementary RNA was generated with the Illumina TotalPrep RNA Amplification Kit and hybridised with Illumina HumanHT-12 v4 Expression BeadChips (Illumina) as per manufacturer's protocol.
Expression data from the microarrays was analysed as previously described (25). The microarray data reported in this article have been deposited in NCBI's Gene Expression Omnibus (GEO) database under the accession number GSE58074. Chromatin immunoprecipitation (ChIP) was conducted using the SimpleChIP Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling) in accordance with the manufacturer's instructions.
shRNA studies, siRNA delivery and transfections
Control and overexpression plasmids and siRNAs used for manipulating E2F7 have been described previously (10, 17) . SureSilencing shRNA plasmids directed against Sphk1 were purchased from SuperArray Bioscience Corp. A Sphk1 expression (TrueORF Gold Clones) and control plasmids were purchased from OriGene Technologies.
Immunoblot
The following primary antibodies were used: E2F-1 (C-20) 1:1,000 (Santa Cruz), Anti-E2F7 1:2,000 (Abcam), cleaved caspase-3 (Asp 175) 1:1,000 (Cell Signaling), Anti-SPHK1 1:1,000 (Sigma), PARP 1:1,000 (Cell Signaling), phospho-Akt (Ser473) (D9E) XP 1:2,000 (Cell Signaling), Akt 1:2,000 (Cell Signaling), and β-actin 1:10,000 (Sigma Aldrich). Where a western blot has been quantitated, results represent relative protein levels normalised to β-actin as quantified by Image J (Wayne Rasband, National Institutes of Health, USA).
Immunohistochemistry and tissue microarrays
Research. DOI: 10.1158 /1078 -0432.CCR-14-1962 Immunohistochemistry was conducted as described (20, 21) . The following primary antibodies were used: PCNA 1:3,000 (Sigma Aldrich), cleaved caspase-3 (Asp 175) 1:50 (Cell Signaling), phospho-Akt (Ser473) (D9E) XP 1:50 (Cell Signaling). Secondary antibody was Starr Trek Universal HRP Detection System followed by colorimetric immunohistochemical staining with Cardassian DAB Chromogen as per manufacturer's instructions (Biocare Medical). TMAs were generated using duplicate 1 mm cores of matched a) adjacent normal tissue, b) primary HNSCC lesion and c) matched metastatic lymph node from patients treated for HNSCC at the PAH. Immunohistochemistry was conducted using Dako EnVision + System-HRP (DAB) kit in accordance with the manufacturer's instructions. Sections were incubated with Anti-E2F7 1:250 (Abcam) and Anti-SPHK1 1:75 (Sigma Aldrich) antibodies. Staining intensity was evaluated by two Pathologists in a blinded fashion using a modified quickscore method as described (26).
Statistical analysis
Statistical significance was calculated by a Student's t test with a 95% confidence level using GraphPad Prism v5 (GraphPad software).
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Results
E2F7 selectively regulates cytotoxic responses to doxorubicin in KCs
To examine the downstream pathways involved we generated primary cultures of MEKs from E2f1 KO mice (15) Figure S1 ). The reduction in E2f1 expression was less than expected but sequencing confirmed the PCR product was E2f1. Significantly, infection with an empty Ad viral vector did not alter cell viability, mRNA expression, differentiation-competence or cytotoxic responses to UVB, doxorubicin or cisplatin ( Figure   S2 ).
We examined the dose-dependent cytotoxic profiles of uninfected control, E2f7 KD, E2f8 KD and E2f1KO cells to increasing concentrations of doxorubicin (0-1 µM) for 48 hours. E2f7 deficient MEKs were hypersensitive to the cytotoxic actions of doxorubicin ( Figure 1A ) or another anthracycline, epirubicin ( Figure S3A ). Significantly, E2f7 deficiency only had minimal effect on cisplatin sensitivity ( Figure S3B ) and no impact on etoposide sensitivity ( Figure S3C ). E2f8 had no effect on cytotoxic responses to any of the drugs ( Figures 1A and   S3 ) whilst E2f1 deficiency resulted in modest protection against doxorubicin-induced cytotoxicity ( Figure 1A ). To confirm that the effect of E2f7 deficiency was attributable to DOI: 10.1158 /1078 -0432.CCR-14-1962 doxorubicin resistance ( Figure 1B ). We then determined whether E2f7-mediated reduction in cell survival is due to activation of apoptotic pathways. Uninfected control MEKs isolated from floxed E2f7 mice showed a modest increase in cleaved caspase-3 levels after 48 hours treatment with 0.3 µM doxorubicin ( Figure 1C ). In contrast, there was a profound activation of caspase-3 when E2f7 deficient MEKs were treated with 0.3 μM doxorubicin ( Figure 1C ).
Combined, these data identify a unique and isoform-specific function of E2f7 in modulating sensitivity to anthracyclines in KCs.
Dysregulation of E2F7 expression in human SCC cell lines contributes to insensitivity to the cytotoxic action of doxorubicin
It is reasonable to speculate that the overexpression of E2F7, observed in human SCCs (10) , may invoke insensitivity to doxorubicin. We screened a suite of SCC cell lines (FaDu, KJDSV40 and SCC25) as well as normal human epidermal keratinocytes (HEKs) for their sensitivity to doxorubicin-induced cytotoxicity ( Figure 1D ). These studies showed that KJDSV40 cell lines were the most sensitive to doxorubicin treatment with 70% reduction in cell viability at 1 µM ( Figure 1D ). On the other hand, SCC25 cells displayed the least sensitivity where 80% of the cells were still viable at 1 µM ( Figure 1D ). Examination of E2F1 and E2F7 protein expression levels demonstrated that insensitive SCC25 cells had high levels of E2F7 to E2F1 whilst sensitive KJDSV40 cells had low levels of E2F7 relative to E2F1 ( Figure 1E ). Overall the insensitive SCC25 cells had 10 fold greater E2F7 expression relative to E2F1 than did sensitive KJDSV40 cells. It was not possible to generate values for the HEKs due to their low levels of expression of E2F1 and E2F7.
We next sought to determine whether selective upregulation or reduction of E2F7 expression by expression plasmid or siRNA (validation of siRNA is shown in Figure S4A) DOI: 10.1158 /1078 -0432.CCR-14-1962 would change the dose response profile of KJDSV40 and SCC25 cells to doxorubicin.
Results showed that previously sensitive KJDSV40 cells became resistant to doxorubicin compared to vector only control cells when transfected with E2F7 expression plasmid ( Figure   1F ). In contrast, silencing of E2F7 in insensitive SCC25 cells resulted in a 2.2 fold reduction in E2F7 mRNA expression determined by qRT-PCR and could enhance doxorubicin-induced cytotoxicity compared to control siRNA transfected SCC25 cells ( Figure 1G) . These data unequivocally demonstrate that resistance to doxorubicin is E2F7-dependent in SCC cells.
Sphingosine kinase 1 (Sphk1) is a downstream effector of E2F7-mediated suppression of doxorubicin-induced cytotoxicity
To identify the downstream effectors of E2F7 in SCC cells, we generated transcriptomic profiles for differentially expressed transcripts between the KJDSV40 cells (sensitive and low E2F7/E2F1 ratio) and SCC25 cells (insensitive and high E2F7/E2F1 ratio). We also generated a list of upregulated genes between SCC25 cells and SCC25 cells in which E2F7 had been silenced with siRNA. This latter list identified E2F7-modulated transcripts which were then cross-referenced against the list of genes identified as downregulated in KJDSV40 cells compared with SCC25 cells. A detailed explanation of this analysis is being prepared for publication elsewhere (Hazar-Rethinam et al, in preparation) . By selecting for genes with a B-value greater than 3 (exceeding the 95% confidence interval) and a fold change greater than 1, we were able to identify 4 genes (Sphk1, RACGAP1, CD44, RRP8) that were differentially upregulated.
Of the transcripts identified in our screen, sphingosine kinase 1 (Sphk1) was the most significantly overexpressed. Sphk1 is a kinase responsible for the conversion of sphingosine to sphingosine-1-phosphate (S1P) (27) (28) (29) DOI: 10.1158 /1078 -0432.CCR-14-1962 indicates statistically significant increases in Sphk1 expression in breast, colon, lung, ovary, prostate, melanoma, stomach, uterus as well as squamous cell carcinoma and it's precursor actinic keratosis (28). Importantly, Sphk1 has been shown to modulate proliferation, Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 siRNA ( Figure 2D , Right panel). These data unequivocally demonstrate that Sphk1 is the downstream effector of E2F7-dependent sensitivity of SCC cells to doxorubicin. It remains unclear whether Sphk1 is a direct or indirect target of E2F7. In this regard, ChIP assays showed that E2F7 could bind the Sphk1 and E2F1 promotersin SCC25 cells compared with low levels of binding in KJDSV40 cells indicating that the Sphk1 and E2F1 promoters are direct binding targets of E2F7 ( Figure 2E ).
Next, we sought to determine whether there was evidence that Sphk1 was overexpressed in primary human SCC tumours. We have generated tissue microarrays (TMAs) comprising duplicates of normal, primary tumour and matched metastasis from HNSCC patients treated at the Princess Alexandra Hospital (PAH), Queensland, Australia. The TMAs were stained for E2F7 and Sphk1 protein expression by immunohistochemistry and scored by two
Pathologists. Figure 2F shows that Sphk1 and E2F7 are overexpressed in HNSCC compared to matched adjacent normal tissue. Figure 2F also shows that primary tumour and metastatic tumour do not differ significantly in the levels of E2F7 or Sphk1.
Sphk1 inhibition sensitizes SCC cells to doxorubicin-induced cytotoxicity
In order to determine whether Sphk1 contributes to doxorubicin sensitivity, we studied the effects of silencing Sphk1 in insensitive SCC25 cells. Sphk1 gene silencing was achieved via shRNA and caused a marked decrease in Sphk1 protein level ( Figure 3A ), Sphk1 enzyme activity ( Figure 3B ) and S1P (a product of Sphk1) measured in cell lysates ( Figure 3C ) and significantly enhanced sensitivity of SCC25 cells to doxorubicin ( Figure 3D ). Conversely, overexpression of Sphk1 in insensitive KJDSV40 cells resulted in increases in Sphk1 protein level ( Figure 3E ), enzyme activity ( Figure 3F ), S1P production ( Figure 3G ) and reduced sensitivity to doxorubicin compared to vector control ( Figure 3H ). S1P is the product of Sphk1-catalysed phosphorylation of sphingosine, and has been shown to mediate the anti- Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 apoptotic effects of Sphk1 (27, 29) . Consistent with this, we found that treatment of KJDSV40 cells with 1 M S1P reduced cytotoxicity by 2.6 fold ( Figure 3I ). Combined, these data indicate that sensitivity to doxorubicin is mediated via a novel E2F7/Sphk1/S1P axis in SCCs.
Knockdown of Sphk1 sensitizes resistant SCC cells to doxorubicin-induced cytotoxicity in vivo
Our data suggest that inhibition of Sphk1 activity, in combination with doxorubicin, may be a Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 been treated with 0.5 mg/kg doxorubicin (Figures 4C and 4D ; red square), we started to treat these mice when their tumours reached around 0.5 cm 3 with 0.5mg/kg doxorubicin ( Figure   4D ). As shown in Figure 4D , doxorubicin treatment dramatically reduced the tumour volume showing profound regression one week after doxorubicin was started in Sphk1 deficient group of animals as compared with those inoculated with control vector ( Figure 4D ). All mice were sacrificed at day 28 post-treatment when the tumour burden in the control mice reached the ethically approved maximum size. Upon autopsy, the mice inoculated with the Sphk1-deficient SCC cells (Figures 4C and 4D ; green triangle) only contained a fragile cluster of cellular material that could not be harvested for histopathology.
The Sphk1 specific inhibitor, SK1-I (BML-EI411), sensitises SCC cells to doxorubicin in vitro and in vivo
SK1-I is a water-soluble sphingosine analog with a Ki value of approximately 10 µM which potently inhibits Sphk1 activity (33). Importantly, SK1-I does not significantly inhibit SPHK2, PKA, AKT1, ERK1, EGFR or CDK2 (33). We treated SCC25 cells with increasing doses of SK1-I for 48 hours and then measured Sphk1 enzyme activity. As anticipated, SK1-I significantly reduced Sphk1 activity in a dose-dependent manner, indicating inhibition of Sphk1 activity ( Figure 5A ). Moreover, we confirmed that the inhibition was not due to the loss of Sphk1 protein expression ( Figure 5B ).
Next, we investigated whether Sphk1 specific inhibition can enhance the cytotoxic effects of doxorubicin in insensitive SCC25. After 48 hours incubation with SK1-I alone, the viability of control HEK ( Figure S5A ) and resistant SCC25 cells did not change ( Figure 5C ).
However, treatment of doxorubicin-resistant SCC25 cells with 1 µM doxorubicin with increasing doses of SK1-I resulted in profound and dose dependent loss of cell viability
Research. DOI: 10.1158 /1078 -0432.CCR-14-1962 ( Figure 5C ). Predictably, SK1-I did not enhance doxorubicin sensitivity in KJDSV40 cells ( Figure S5B ). In contrast to SCC25 cells, the addition of increasing doses of SK1-I to doxorubicin, in HEKs, did not enhance the cytotoxicity obtained with doxorubicin alone ( Figure S5A ). Next, we examined whether the cell death effects of SK1-I and doxorubicin were mediated via apoptosis. Consistent with an apoptotic reaction, we observed increases in cleaved caspase-3 and cleaved PARP1 in response to doxorubicin + SK1-I ( Figure 5D ). DOI: 10.1158 /1078 -0432.CCR-14-1962 Sphk1/S1P has been shown to exert its antiapoptotic activity via signaling through a family of S1P receptors linked to the PI3K/AKT pathway (34, 35) . Consistent with this, we found that SK1-I could reduce phospho-AKT (p-AKT) (Ser473) in a dose dependent manner ( Figure   6A ). Previous reports have shown that p-AKT is a downstream effector of the pro-survival effects of increased Sphk1 activity and S1P production (36). Moreover, it is established that the PI3K/AKT pathway is frequently dysregulated via mutations in PI3K family members, gene amplifications or pathway activation in HNSCC (37). Thus, we examined whether E2F7 induced prosurvival responses were mediated via increased Sphk1/S1P and subsequent AKT Figures 6D and 6E ). These data indicate that the changes in AKT activity lie downstream of Sphk1, which in turn is downstream of E2F7. These data would predict that the profound tumour regression observed as a result of a doxorubicin/SK1-I combination could be recapitulated using doxorubicin + AKT inhibitor.
We have previously shown that the mTOR/PI3K inhibitor, BGT226, is able to reduce tumour growth rates in mice transplanted with SCC cells (19). In the present study, mice were DOI: 10.1158 /1078 -0432.CCR-14-1962 weekly. Tumour growth in the vehicle control (DMSO) and doxorubicin treated mice was unchanged whilst those mice treated with BGT226 alone displayed a modest reduction in tumour growth rate ( Figure 6F ). Mice treated with the doxorubicin/BGT226 combination displayed significant regression of the tumour mass ( Figure 6F ).
We next examined levels of PCNA, cleaved caspase-3 and p-AKT levels within the tumours 
DISCUSSION
In the present study we provide, in vitro, in vivo and patient data that identifies a novel E2F7/Sphk1/S1P/AKT axis that regulates sensitivity to anthracyclines in SCC. Specifically, we show that (i) E2F7 selectively modulates sensitivity to doxorubicin in KCs and SCC, (ii) that E2F7-dependent doxorubicin resistance is mediated via induction of Sphk1 which in turn activates AKT and (iii) that pharmacological inhibition of Sphk1 or AKT sensitizes SCC cells to the cytotoxic actions of doxorubicin in vitro and in vivo. Combined, these findings highlight a novel mechanism through which SCC cells acquire resistance to anthracyclines. Overall, current data relating to the mechanisms regulating E2F control of apoptosis are complex. For example, E2F1 is known to be induced by cytotoxic stimuli and DNA damage (7, 8) . This induction can occur at the level of post-translational modification and protein stabilization and/or can occur through increased E2F1 transcription (16, 38) . The main outcome of the increased E2F activity is mediated via ARF stimulated inhibition of MDM2 resulting in increased p53-dependent apoptosis. However, complicating this is the observation that E2F1 can recognize double strand breaks induced by UV and recruit NER machinery to the DNA break (16) . In this way E2F1 has been proposed to display antiapoptotic actions (16) . This latter pathway has been demonstrated to exist in normal MEKs (39). Further complicating this is the observation that E2F7 can antagonize the pro-apoptotic activity of E2F1 in embryonic tissues as well as in normal or cancer cells (10, 17, 18, 40) .
Thus, in order to determine the role of E2F7 in regulating cytotoxic responses in HNSCC it is important to consider the tissue context and the nature of the cytotoxic stimulus or DNA damage.
In the present study we show that E2F7 and E2F1 suppress and induce doxorubicin sensitivity in SCC cells respectively. . We also show that cytotoxic responses to etoposide or cisplatin were not altered by E2F7. Since doxorubicin and etoposide are established type II topoisomerase blocking agents, and E2F7 did not alter etoposide sensitivity it is reasonable to suggest that the effects of E2F7 were independent of the topoisomerase inhibitory actions of doxorubicin. We also show that regulation of doxorubicin sensitivity in SCC cells is E2F isoform-specific since the other inhibitory E2F, E2F8, did not modify the sensitivity of KCs to doxorubicin or any other drug studied. In addition, we show that E2F7 suppresses doxorubicin sensitivity via increases in the expression of Sphk1 resulting in increased levels of S1P which in turn enhance the Ser473 p-AKT-dependent pro-survival response. The E2F- dependence of S1P/AKT-mediated drug resistance has not been described before and has significant pathological and clinical implications in SCC.
The relevance of an E2F/Sphk1/S1P/AKT axis in SCC is highlighted by a number of independent observations. In particular E2F1 (5, 11), E2F7 (10), Sphk1 (30, 42), S1P (41), PI3K and AKT (37) are all increased in SCC. Part of these increases may be explained by activation of signaling pathways that regulate their activity/expression such as MAPKmediated activation of AKT and/or Sphk1 (35, 37) or disrupted Rb activity mediated via p16 deletion or cyclin D amplification for E2F1/E2F7 (7, 8) . However, PI3K/AKT is commonly mutated or amplified in SCC (2, 3, 37) . Regardless of the underlying mechanism it is clear that the individual members of the E2F/Sphk1/S1P/AKT axis are all overexpressed and active in SCC. Whilst the events that initiate disruption of this axis remain unknown it is likely that dysregulation of the E2F/Rb or PI3K/AKT pathway result from mutational events early in tumour formation which could lead to overexpression of E2F7 (a direct E2F1 target) and Sphk1 (a direct E2F7 target). The mechanism by which E2F7 induces Sphk1 transcription was not established in this study. Although E2F7 is an established transcriptional repressor, it has recently been reported that an E2F7-HIF1 transcriptional complex activates the transcription of VEGFA (42). Thus, it is a formal possibility that E2F7 may be a direct activator of Sphk1 transcription. Alternatively, E2F7 could act in a dominant-negative manner by blocking the binding of other E2F repressor complexes. Regardless of the mechanism, our functional data shows that E2F7 regulates S1P levels via induction of Sphk1 Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 immunity (29). In particular, ceramide and sphingosine have been shown to be profoundly pro-apoptotic whilst phosphorylated sphingosine (S1P) is profoundly anti-apoptotic (27-29).
Thus, the kinase, Sphk1, responsible for catalyzing the conversion of sphingosine to S1P, is also responsible for changing the physiology of the cell from pro-apoptotic to anti-apoptotic.
Many of the anti-apoptotic effects of S1P are mediated via a family of G protein coupled S1P receptors which in turn activate PI3K/AKT (27) (28) (29) 43) . Interestingly, the use of an AKT inhibitor was able to induce modest levels of cell death and reduced tumour growth in vivo.
Given that Sphk1 inhibitors profoundly inhibited p-AKT (Ser473), these data would suggest that some of the cytotoxic effects observed for BGT226 alone may be mediated via non-AKT targets. Finally, doxorubicin alone displayed no measurable anticancer activity in our xenotransplant model. These data suggest that the cytotoxicity observed with the SK1-I or BGT226 plus doxorubicin combination reflects an unidentified synthetic lethal reaction. The clinical potential for this novel combination (e.g. Sphk1 or AKT inhibitor combined with an anthracycline) is highlighted by the profound tumour regression observed in this study.
A previous report had shown that the activation of AKT in ovarian and breast cancer suppressed E2F1-induced apoptosis and was associated with a poor prognosis and chemoresistance (44). Similarly, Reimer and colleagues reported that poor prognosis and chemoresistance of ovarian tumours was associated with a high E2F7/E2F1 ratio (45). We now provide an integrated model in which E2F7 is causally linked to the overexpression of Sphk1, the activation of the AKT pathway and doxorubicin resistance. This is definitively shown by our observation that Sphk1, S1P and p-AKT (Ser473) Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1962 23 mediated via the PI3K/AKT pathway has been previously reported (35, 36) . What is new in our study is that the dysregulation of the E2F pathway, in SCC, directly activates the Sphk1/S1P/PI3K/AKT pathway resulting in selective resistance to doxorubicin. This is an advance that can be immediately translated to a clinical trial with existing pharmacological agents.
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